---
figid: PMC7312468__ijms-21-04055-g001
figlink: pmc/articles/PMC7312468/figure/ijms-21-04055-f001/
number: F1
caption: Schematic of the MNK1/2-eIF4E axis. The red stars on the NRAS, RAF, and NF1
  indicate the three common subtypes of cutaneous melanoma. Mutations in BRAF result
  in the hyperactivation of the mitogen-activated protein kinase (MAPK) pathway while
  mutations in NRAS or NF1 result in the hyperactivation of both MAPK and phosphoinositide
  3-kinase (PI3K) pathways. Activating mutations in c-KIT results in hyperactivation
  of Ras and downstream effector pathways. Signaling down the MAPK pathway results
  in the activation of MNK1/2 and signaling down the PI3K/Akt pathway results in the
  hyperphosphorylation of 4E-BP and the resultant release of eIF4E to associate with
  eIF4G. MNK1/2 bind to eIF4G and phosphorylate eIF4E at Ser209. This results in enhanced
  translation of certain mRNAs. MNK1 and MNK2 may also be phosphorylated by p38 through
  stress-mediated signals.
pmcid: PMC7312468
papertitle: The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma.
reftext: Sathyen A. Prabhu, et al. Int J Mol Sci. 2020 Jun;21(11):4055.
pmc_ranked_result_index: '36399'
pathway_score: 0.9582863
filename: ijms-21-04055-g001.jpg
figtitle: The MNK1/2-eIF4E axis
year: '2020'
organisms:
- Cricetulus griseus
- Mus musculus
- Rattus norvegicus
- Coronaviridae
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7312468__ijms-21-04055-g001.html
  '@type': Dataset
  description: Schematic of the MNK1/2-eIF4E axis. The red stars on the NRAS, RAF,
    and NF1 indicate the three common subtypes of cutaneous melanoma. Mutations in
    BRAF result in the hyperactivation of the mitogen-activated protein kinase (MAPK)
    pathway while mutations in NRAS or NF1 result in the hyperactivation of both MAPK
    and phosphoinositide 3-kinase (PI3K) pathways. Activating mutations in c-KIT results
    in hyperactivation of Ras and downstream effector pathways. Signaling down the
    MAPK pathway results in the activation of MNK1/2 and signaling down the PI3K/Akt
    pathway results in the hyperphosphorylation of 4E-BP and the resultant release
    of eIF4E to associate with eIF4G. MNK1/2 bind to eIF4G and phosphorylate eIF4E
    at Ser209. This results in enhanced translation of certain mRNAs. MNK1 and MNK2
    may also be phosphorylated by p38 through stress-mediated signals.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - NRAS
  - NF1
  - PTEN
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - BRAF
  - MAP2K1
  - MAP2K2
  - AKT2
  - AKT3
  - AKT1
  - MAP2K3
  - MAP2K6
  - MTOR
  - MAPK3
  - MAPK1
  - MKNK1
  - MKNK2
  - EIF4E
  - EIF4A3
  - EIF4A1
  - EIF4A2
  - EIF4G1
  - EIF4G2
  - EIF4G3
  - imatinib
  - nilotinib
  - dasatinib
  - vemurafenib
  - dabrafenib
  - encorafenib
  - cobimetinib
  - trametinib
  - binimetinib
  - LY2275796
  - cercosporamide
  - CGP57380
  - Silvestrol
  - Pateamine A
  - Hippuristanol
genes:
- word: NRAS
  symbol: NRAS
  source: hgnc_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: NF1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: МЕК1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MKK3/6
  symbol: MKK3
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K3
  entrez: '5606'
- word: MKK3/6
  symbol: MKK6
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K6
  entrez: '5608'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MNK1/2
  symbol: MNK1
  source: hgnc_alias_symbol
  hgnc_symbol: MKNK1
  entrez: '8569'
- word: MNK1/2
  symbol: MNK2
  source: hgnc_alias_symbol
  hgnc_symbol: MKNK2
  entrez: '2872'
- word: elF4E
  symbol: EIF4E
  source: hgnc_symbol
  hgnc_symbol: EIF4E
  entrez: '1977'
- word: EIF4E
  symbol: EIF4E
  source: hgnc_symbol
  hgnc_symbol: EIF4E
  entrez: '1977'
- word: EIF4E
  symbol: EIF4E
  source: hgnc_symbol
  hgnc_symbol: EIF4E
  entrez: '1977'
- word: EIF4A
  symbol: EIF4A
  source: bioentities_symbol
  hgnc_symbol: EIF4A3
  entrez: '9775'
- word: EIF4A
  symbol: EIF4A
  source: bioentities_symbol
  hgnc_symbol: EIF4A1
  entrez: '1973'
- word: EIF4A
  symbol: EIF4A
  source: bioentities_symbol
  hgnc_symbol: EIF4A2
  entrez: '1974'
- word: MNK1/2
  symbol: MNK1
  source: hgnc_alias_symbol
  hgnc_symbol: MKNK1
  entrez: '8569'
- word: MNK1/2
  symbol: MNK2
  source: hgnc_alias_symbol
  hgnc_symbol: MKNK2
  entrez: '2872'
- word: elF4G
  symbol: EIF4G
  source: bioentities_symbol
  hgnc_symbol: EIF4G1
  entrez: '1981'
- word: elF4G
  symbol: EIF4G
  source: bioentities_symbol
  hgnc_symbol: EIF4G2
  entrez: '1982'
- word: elF4G
  symbol: EIF4G
  source: bioentities_symbol
  hgnc_symbol: EIF4G3
  entrez: '8672'
chemicals:
- word: imatinib
  source: MESH
  identifier: C097613
- word: nilotinib
  source: MESH
  identifier: C498826
- word: dasatinib
  source: MESH
  identifier: C488369
- word: vemurafenib
  source: MESH
  identifier: C551177
- word: dabrafenib
  source: MESH
  identifier: C561627
- word: encorafenib
  source: ''
  identifier: ''
- word: cobimetinib
  source: MESH
  identifier: C574276
- word: trametinib
  source: MESH
  identifier: C560077
- word: binimetinib
  source: MESH
  identifier: C581313
- word: LY2275796
  source: MESH
  identifier: C569652
- word: cercosporamide
  source: MESH
  identifier: C085452
- word: CGP57380
  source: MESH
  identifier: C466997
- word: Silvestrol
  source: MESH
  identifier: C489897
- word: Pateamine A
  source: MESH
  identifier: C421324
- word: Hippuristanol
  source: MESH
  identifier: C510125
diseases: []
figid_alias: PMC7312468__F1
redirect_from: /figures/PMC7312468__F1
figtype: Figure
---
